Quick Search:

uzh logo
Browse by:
bullet
bullet
bullet
bullet

Zurich Open Repository and Archive

Permanent URL to this publication: http://dx.doi.org/10.5167/uzh-66728

von Kempis, Johannes; Dudler, Jean; Hasler, Paul; Kyburz, Diego; Tyndall, Alan; Zufferey, Pascal; Villiger, Peter M (2012). Use of abatacept in rheumatoid arthritis. Swiss Medical Weekly, 142:w13581.

[img]
Preview
Published Version
PDF
647kB

View at publisher

Abstract

Abatacept (CTLA-Ig), a modulator of T-lymphocyte activation, has been approved by the Swiss health regulatory agency Swissmedic for the treatment of active rheumatoid arthritis (RA). This article summarises the key trial findings for this biologic agent in RA in different situations such as early erosive rheumatoid arthritis (RA), biologic-naïve RA, RA before and after the use of methotrexate or TNF-inhibitors and includes safety information from these trials. Based on these data, recommendations for clinical practice in Switzerland are made by a panel of experts.

Citations

3 citations in Web of Science®
7 citations in Scopus®
Google Scholar™

Altmetrics

Downloads

6 downloads since deposited on 16 Nov 2012
6 downloads since 12 months

Detailed statistics

Additional indexing

Item Type:Journal Article, refereed, further contribution
Communities & Collections:04 Faculty of Medicine > University Hospital Zurich > Rheumatology Clinic and Institute of Physical Medicine
DDC:610 Medicine & health
Language:English
Date:2012
Deposited On:16 Nov 2012 14:28
Last Modified:16 Apr 2014 18:01
Publisher:EMH Swiss Medical Publishers
ISSN:0036-7672
Free access at:PubMed ID. An embargo period may apply.
Publisher DOI:10.4414/smw.2012.13581
PubMed ID:22581564

Users (please log in): suggest update or correction for this item

Repository Staff Only: item control page